Adaptive Stress Responses During Tumor Metastasis and Dormancy

Trends in Cancer

Volumn 2, Issue 8, 2016, Pages 429-442

  Senft, Daniela ^a   Ronai, Ze'ev A ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

dormancy; metastasis; tumor cell plasticity; unfolded protein response (UPR)

Indexed keywords

REACTIVE OXYGEN METABOLITE;

ADAPTATION; CELL DIFFERENTIATION; CELL PLASTICITY; CELL STRESS; CELL SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE; ANIMAL; METABOLISM; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

ANIMALS; CELL PLASTICITY; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; STRESS, PHYSIOLOGICAL; UNFOLDED PROTEIN RESPONSE;

EID: 84979698218     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.06.004     Document Type: Review

References (113)

1. 1 Luzzi, K.J., et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 153 (1998), 865–873.
2. 2 Klein, C.A., Framework models of tumor dormancy from patient-derived observations. Curr. Opin. Genet. Dev. 21 (2011), 42–49.
3. 3 Giancotti, F.G., Mechanisms governing metastatic dormancy and reactivation. Cell 155 (2013), 750–764.
4. 4 Sosa, M.S., et al. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat. Rev. Cancer 14 (2014), 611–622.
5. 5 Aguirre-Ghiso, J.A., Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7 (2007), 834–846.
6. 6 Fidler, I.J., Kripke, M.L., Metastasis results from preexisting variant cells within a malignant tumor. Science 197 (1977), 893–895.
7. 7 Lawson, D.A., et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526 (2015), 131–135.
8. 8 Dieter, S.M., et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9 (2011), 357–365.
9. 9 Oskarsson, T., et al. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14 (2014), 306–321.
10. 10 Wouters, B.G., Koritzinsky, M., Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 8 (2008), 851–864.
11. 11 Gilkes, D.M., et al. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 14 (2014), 430–439.
12. 12 Semenza, G.L., Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 32 (2013), 4057–4063.
13. 13 Seftor, R.E., et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am. J. Pathol. 181 (2012), 1115–1125.
14. 14 Wagenblast, E., et al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature 520 (2015), 358–362.
15. 15 Ruf, W., et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res. 63 (2003), 5381–5389.
16. 16 Nieto, M.A., Epithelial plasticity: a common theme in embryonic and cancer cells. Science, 342, 2013, 1234850.
17. 17 Thiery, J.P., et al. Epithelial–mesenchymal transitions in development and disease. Cell 139 (2009), 871–890.
18. 18 Labelle, M., et al. Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis. Cancer Cell 20 (2011), 576–590.
19. 19 LeBleu, V.S., et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16 (2014), 992–1003.
20. 20 Luo, X., et al. Isolation and molecular characterization of circulating melanoma cells. Cell Rep. 7 (2014), 645–653.
21. 21 Ting, D.T., et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 8 (2014), 1905–1918.
22. 22 Yu, M., et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339 (2013), 580–584.
23. 23 Brabletz, T., et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. U.S.A. 98 (2001), 10356–10361.
24. 24 Stankic, M., et al. TGF-beta-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep. 5 (2013), 1228–1242.
25. 25 Ye, X., Weinberg, R.A., Epithelial–mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 25 (2015), 675–686.
26. 26 Fischer, K.R., et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 (2015), 472–476.
27. 27 Zheng, X., et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527 (2015), 525–530.
28. 28 Maddipati, R., Stanger, B.Z., Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov. 5 (2015), 1086–1097.
29. 29 Aceto, N., et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158 (2014), 1110–1122.
30. 30 Cheung, K.J., et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), E854–E863.
31. 31 Au, S.H., et al. Clusters of circulating tumor cells traverse capillary-sized vessels. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), 4947–4952.
32. 32 Ward, P.S., Thompson, C.B., Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21 (2012), 297–308.
33. 33 Davidson, S.M., et al. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 23 (2016), 517–528.
34. 34 Hensley, C.T., et al. Metabolic heterogeneity in human lung tumors. Cell 164 (2016), 681–694.
35. 35 Viale, A., et al. Tumors and mitochondrial respiration: a neglected connection. Cancer Res. 75 (2015), 3685–3686.
36. 36 Aguilar, E., et al. Metabolic reprogramming and dependencies associated with epithelial cancer stem cells independent of the epithelial–mesenchymal transition program. Stem. Cells 34 (2016), 1163–1176.
37. 37 Caino, M.C., et al. PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), 8638–8643.
38. 38 Rivadeneira, D.B., et al. Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion. Sci. Signal., 8, 2015, ra80.
39. 39 Torrano, V., et al. The metabolic co-regulator PGC1alpha suppresses prostate cancer metastasis. Nat. Cell Biol. 18 (2016), 645–656.
40. 40 Gorrini, C., et al. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12 (2013), 931–947.
41. 41 Harris, I.S., et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27 (2015), 211–222.
42. 42 Xu, I.M., et al. Transketolase counteracts oxidative stress to drive cancer development. Proc. Natl. Acad. Sci. US.A. 113 (2016), E725–E734.
43. 43 Piskounova, E., et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527 (2015), 186–191.
44. 44 Ishikawa, K., et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320 (2008), 661–664.
45. 45 Porporato, P.E., et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 8 (2014), 754–766.
46. 46 Dey, S., et al. ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. J. Clin. Invest. 125 (2015), 2592–2608.
47. 47 Qu, Y., et al. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-kappaB signaling. J. Clin. Invest. 121 (2011), 212–225.
48. 48 Le Gal, K., et al. Antioxidants can increase melanoma metastasis in mice. Sci. Transl. Med., 7, 2015, 308re308.
49. 49 Schafer, Z.T., et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461 (2009), 109–113.
50. 50 Dupuy, F., et al. PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab. 22 (2015), 577–589.
51. 51 Loo, J.M., et al. Extracellular metabolic energetics can promote cancer progression. Cell 160 (2015), 393–406.
52. 52 Nguyen, A., et al. PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. J. Clin. Invest. 126 (2016), 681–694.
53. 53 Jungermann, K., Kietzmann, T., Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 31 (2000), 255–260.
54. 54 Mashimo, T., et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159 (2014), 1603–1614.
55. 55 Nieman, K.M., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17 (2011), 1498–1503.
56. 56 Kaplan, R.N., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005), 820–827.
57. 57 Psaila, B., Lyden, D., The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 9 (2009), 285–293.
58. 58 Wong, C.C., et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 16369–16374.
59. 59 Cox, T.R., et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522 (2015), 106–110.
60. 60 Erler, J.T., et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15 (2009), 35–44.
61. + immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 72 (2012), 3906–3911.
62. 62 Fong, M.Y., et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17 (2015), 183–194.
63. 63 Aguirre Ghiso, J.A., Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21 (2002), 2513–2524.
64. 64 Barkan, D., et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 68 (2008), 6241–6250.
65. 65 Shibue, T., Weinberg, R.A., Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 10290–10295.
66. 66 Lahlou, H., et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 20302–20307.
67. 67 Liu, D., et al. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1 (2002), 445–457.
68. 68 Barkan, D., et al. Metastatic growth from dormant cells induced by a Col-I-enriched fibrotic environment. Cancer Res. 70 (2010), 5706–5716.
69. 69 Cox, T.R., et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 73 (2013), 1721–1732.
70. 70 Ghajar, C.M., et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 15 (2013), 807–817.
71. 71 Taichman, R.S., et al. GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS ONE, 8, 2013, e61873.
72. 72 Sosa, M.S., et al. NR2F1 controls tumour cell dormancy via SOX9- and RARbeta-driven quiescence programmes. Nat. Commun., 6, 2015, 6170.
73. 73 Kobayashi, A., et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J. Exp. Med. 208 (2011), 2641–2655.
74. 74 Bragado, P., et al. TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nat. Cell Biol. 15 (2013), 1351–1361.
75. 75 Gao, H., et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150 (2012), 764–779.
76. 76 Malladi, S., et al. Metastatic latency and Immune evasion through autocrine inhibition of WNT. Cell 165 (2016), 45–60.
77. 77 Lopez-Maury, L., et al. Tuning gene expression to changing environments: from rapid responses to evolutionary adaptation. Nat. Rev. Genet. 9 (2008), 583–593.
78. 78 Senft, D., Ronai, Z.A., UPR, autophagy, and mitochondria crosstalk underlies the ER stress response. Trends Biochem. Sci. 40 (2015), 141–148.
79. 79 Wang, M., Kaufman, R.J., The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat. Rev. Cancer 14 (2014), 581–597.
80. 80 Feng, Y.X., et al. Epithelial-to-mesenchymal transition activates PERK–eIF2alpha and sensitizes cells to endoplasmic reticulum stress. Cancer Discov. 4 (2014), 702–715.
81. 81 Mujcic, H., et al. Hypoxic activation of the PERK/eIF2alpha arm of the unfolded protein response promotes metastasis through induction of LAMP3. Clin. Cancer Res. 19 (2013), 6126–6137.
82. 82 Nagelkerke, A., et al. Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response. Breast Cancer Res., 15, 2013, R2.
83. 83 Chen, X., et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature 508 (2014), 103–107.
84. 84 Bartkowiak, K., et al. Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. J. Proteome Res. 9 (2010), 3158–3168.
85. 85 Ranganathan, A.C., et al. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 66 (2006), 1702–1711.
86. 86 Chery, L., et al. Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget 5 (2014), 9939–9951.
87. 87 Bartkowiak, K., et al. Disseminated tumor cells persist in the bone marrow of breast cancer patients through sustained activation of the unfolded protein response. Cancer Res. 75 (2015), 5367–5377.
88. 88 Schewe, D.M., Aguirre-Ghiso, J.A., ATF6alpha–Rheb–mTOR signaling promotes survival of dormant tumor cells in vivo. Proc. Natl. Acad Sci. U.S.A. 105 (2008), 10519–10524.
89. 89 Zhang, X.H., et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16 (2009), 67–78.
90. 90 Chen, Q., et al. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20 (2011), 538–549.
91. 91 Correa, R.J., et al. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids. Carcinogenesis 33 (2012), 49–58.
92. 92 Kroemer, G., et al. Autophagy and the integrated stress response. Mol. Cell 40 (2010), 280–293.
93. 93 Leprivier, G., et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 153 (2013), 1064–1079.
94. 94 Holcik, M., Could the eIF2alpha-independent translation be the Achilles heel of cancer?. Front. Oncol., 5, 2015, 264.
95. 95 Starck, S.R., et al. Translation from the 5’ untranslated region shapes the integrated stress response. Science, 351, 2016, aad3867.
96. 96 Marciniak, S.J., et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 18 (2004), 3066–3077.
97. 97 Han, J., et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat. Cell Biol. 15 (2013), 481–490.
98. 98 Flaherty, D.P., et al. Discovery of sulfonamidebenzamides as selective apoptotic CHOP pathway activators of the unfolded protein response. ACS Med. Chem. Lett. 5 (2014), 1278–1283.
99. 99 Bywater, M.J., et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 22 (2012), 51–65.
100. 100 Konicek, B.W., et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 71 (2011), 1849–1857.
101. 101 Pettersson, F., et al. Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis. Cancer Res. 75 (2015), 1102–1112.
102. 102 Devlin, J.R., et al. Combination therapy targeting Ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma. Cancer Discov. 6 (2016), 59–70.
103. 103 Holmgren, L., et al. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1 (1995), 149–153.
104. 104 Koebel, C.M., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007), 903–907.
105. 105 Muller-Hermelink, N., et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13 (2008), 507–518.
106. 106 Shiozawa, Y., et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121 (2011), 1298–1312.
107. 107 Zervantonakis, I.K., et al. Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 13515–13520.
108. 108 Binet, F., Sapieha, P., ER tress and Angiogenesis. Cell Metab. 22 (2015), 560–575.
109. 109 Katanasaka, Y., et al. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. Int. J. Cancer 127 (2010), 2685–2698.
110. 110 Karali, E., et al. VEGF signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. Mol. Cell 54 (2014), 559–572.
111. 111 Eyles, J., et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Invest. 120 (2010), 2030–2039.
112. 112 Cubillos-Ruiz, J.R., et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161 (2015), 1527–1538.
113. 113 Mahadevan, N.R., et al. Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 6561–6566.